Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in contrast with imatinib, for the first-line treatment method of CML-CP. Five hundred and nineteen patients with recently diagnosed CML-CP had been randomly assigned to obtain dasatinib at a dose of 100 mg as soon as day by https://sparkyv752kpt5.wikicarrier.com/user